

AMENDMENTS TO THE CLAIMS

1-12. (Canceled)

13. (Currently amended) A method for enhancing glucose uptake into warm-blooded animal cells, comprising administering to a warm-blooded animal in need thereof an effective amount of ~~one or more HMG-CoA reductase inhibitor(s)~~ pravastatin or pharmacologically acceptable salts or esters thereof.

14. (Withdrawn-Currently amended) A method for enhancing glucose uptake into warm-blooded animal cells in the presence of insulin, comprising administering to a warm-blooded animal in need thereof an effective amount of ~~one or more HMG-CoA reductase inhibitor(s)~~ pravastatin or pharmacologically acceptable salts or esters thereof.

15-18. (Canceled)

19. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or prophylaxis of diabetes complications in a warm-blooded animal, comprising administering to a warm-blooded animal in need of such treatment an effective amount of ~~one or more medicament(s) selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin, and rosuvastatin~~ or pharmacologically acceptable salts or esters thereof.

20. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or prophylaxis of diabetes complications in a warm-blooded animal, caused by insulin resistance

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

syndrome, comprising administering to a warm-blooded animal in need of such treatment an effective amount of ~~one or more medicament(s) selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin, and rosuvastatin~~ or pharmacologically acceptable salts or esters thereof.

21. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or prophylaxis of diabetes complications in a warm-blooded animal, comprising administering to a warm-blooded animal in need of such treatment an effective amount of ~~one or more water-soluble HMG-CoA reductase inhibitor(s)~~ pravastatin or pharmacologically acceptable salts or esters thereof.

22. (Withdrawn-Currently amended) A method for the treatment of diabetes, hyperglycemia, glucose intolerance, or gestational diabetes mellitus, or the treatment or prophylaxis of diabetes complications in a warm-blooded animal, caused by insulin resistance syndrome, comprising administering to a warm-blooded animal in need of such treatment an effective amount of ~~one or more water-soluble HMG-CoA reductase inhibitor(s)~~ pravastatin or pharmacologically acceptable salts or esters thereof.

23-24. (Canceled)

25. (Previously presented) A method according to claim 13, wherein the warm-blooded animal is a human.

26. (Withdrawn) A method according to any one of claims 19, 20, 21, or 22, wherein the diabetes complication is retinopathy, nephropathy, neuropathy, cataract disease, or coronary artery disease.

27-30. (Canceled)

31. (Currently amended) A method according to claim 13, wherein administering an effective amount ~~one or more reductase inhibitors~~ of pravastatin or pharmacologically acceptable salts or esters thereof comprises administering ~~the inhibitors~~ pravastatin or pharmacologically acceptable salts or esters thereof in the presence of insulin.

32. (New) A method according to claim 13 further comprising administering an effective amount of second HMG-CoA reductase inhibitor.

33. (New) A method according to claim 32, wherein the second HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin, and rosuvastatin.

34. (New) A method according to claim 31 further comprising administering an effective amount of second HMG-CoA reductase inhibitor.

35. (New) A method according to claim 34, wherein the second HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin, and rosuvastatin.